ApiJect Systems

Last updated
ApiJect Systems
Industry Medical technology
Founded2018;6 years ago (2018)
Founder Marc Koska
Headquarters Stamford, Connecticut
Key people
[1]
ProductsPre-filled Injectors
Website apiject.com

ApiJect Systems Corporation is an American company founded in 2018 by Marc Koska [2] and based in Stamford, Connecticut [3] that produces pre-filled single use plastic injectors. [4] ApiJect works with pharmaceutical and biotech companies to fill their injectable drug products into single-dose prefilled injectors. [5] [6] The company claimed to have the capacity to manufacture pre-filled COVID-19 vaccine syringes [7] [8] by the end of 2020. [9]

Contents

History

ApiJect Systems was founded in 2018 by Marc Koska, who invented the ApiJect injector, a prefilled, single-use plastic injector, as a low cost way to get medicine to poorer countries. [4] [10] Koska previously invented the self-locking K1 syringe to prevent needle reuse. [11]

In 2020, ApiJect pivoted in order to meet U.S. demand for COVID-19 vaccinations. In May 2020, the U.S. Department of Health and Human Services and the U.S. Department of Defense signed a $138 million deal with ApiJect, called Project Jumpstart, to facilitate the production of 100 million prefilled syringes by the end of 2020 and 500 million in 2021 in the event that a COVID-19 vaccine became available. [12] [10]

In November 2020, ApiJect was approved for a $590 million loan from the U.S. International Development Finance Corporation to construct a multi-facility campus. [13] The project broke ground in February 2021 in Durham, North Carolina, and was among the largest projects in the nation to break ground that month. [14] The factory is designed to deliver production capacity of up to 2 to 3 billion units annually. [15] It will be suitable for vaccines requiring standard cold storage, including those in need of ultra-cold storage down to -70 degrees Celsius. [13]

As of April 21, 2021 the company has failed to produce any syringes, [16] however it has met its obligations under its federal contracts and loan commitments by lining up a subcontractor that promises to produce the syringes once they obtain FDA approval. [17] The CEO of the company stated in July 2020: "The fact of this matter is, it would be crazy for people to just rely on us...We should be America’s backup at this point, but probably not its primary.” [18] According to the White House 100 Days report of June 2021, Health and Human Services is planning to expand Project Jumpstart to $250 million per month through 2023. [19]

In December 2021, ApiJect and Fareva announced a licensing agreement to establish three Blow-Fill-Seal manufacturing lines in France. [20]

In April 2022, ApiJect opened the ApiJect Technology Development Center in Florida, with research and development investment from the U.S. Office of the Assistant Secretary for Preparedness and Response and the U.S. Department of Defense. The center works with pharmaceutical companies to develop prefilled injectors. [21] [22]

In May 2022, ApiJect raised $111 million from Royalty Pharmaceuticals and Jefferies Financial Group, valuing ApiJect at approximately $300 million. [23] [24]

Product

ApiJect’s prefilled injector uses Blow-Fill-Seal (BFS) manufacturing technology, [15] which is recognized as an advanced aseptic liquid packaging process. [25]   The prefilled injector is created by screwing the pen needle-style hub onto the top of the BFS container. [25] BFS process uses pharmaceutical-grade plastic resin to create, fill and seal a strip of 12-to-25 drug containers per production line every three seconds. [13]

Related Research Articles

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Jet injector</span> Needle-free medical injection syringe

A jet injector is a type of medical injecting syringe device used for a method of drug delivery known as jet injection. A narrow, high-pressure stream of liquid is made to penetrate the outermost layer of the skin to deliver medication to targeted underlying tissues of the epidermis or dermis, fat, or muscle.

<span class="mw-page-title-main">CSL Limited</span> Australian biotechnology company

CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Marc Koska</span> British businessman

Marc Andrew Koska OBE is best known for inventing the non-reusable K1 auto-disable syringe, thus preventing the medical transmission of blood-borne diseases.

<span class="mw-page-title-main">Cambrex Corporation</span> American pharmaceutical company

Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets for API and dosage form development and manufacturing.

<span class="mw-page-title-main">Patheon</span> Pharmaceutical company

Patheon is a service brand within Thermo Fisher Scientific's brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging. In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.

<span class="mw-page-title-main">Wockhardt</span> Pharmaceutical and biotechnology company headquartered in Mumbai, India

Wockhardt is an Indian pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.

<span class="mw-page-title-main">Vetter Pharma</span>

Vetter Pharma-Fertigung GmbH & Co. KG is a German pharmaceutical service provider founded in 1950. It is headquartered in Ravensburg, Baden-Württemberg, and has production sites in Germany, Austria, the United States, as well as sales offices in Singapore, Japan, and South Korea. The company develops, manufactures and packages aseptically prefilled syringes, cartridges, and vials.

Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals.

The pharmaceutical industry in Pakistan was estimated to be worth Rs. 748 billion (US$2.6 billion) in 2023, representing about 1% of the country's GDP. The industry is largely import-dependent, with more than 90% of raw material being imported and only 12% of APIs locally produced. Pakistani pharmaceutical companies are engaged in importing raw materials, compounding APIs with excipients, coating of pills, and fill-finish activities. The industry is regulated by the Drug Regulatory Authority of Pakistan, which oversees drug approvals and pricing.

<span class="mw-page-title-main">Aspen Pharmacare</span> Major pharmaceutical company in South Africa

Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange (JSE) in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals (ARVs) and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union.

<span class="mw-page-title-main">Samsung Biologics</span> South Korean biotechnology company

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

<span class="mw-page-title-main">WuXi Biologics</span> Chinese pharmaceutical company

WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.

AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.

Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.

<span class="mw-page-title-main">BioNTech</span> German biotechnology company

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

<span class="mw-page-title-main">Vaccine ingredients</span> Ingredients used in a vaccine dose

A vaccine dose contains many ingredients very little of which is the active ingredient, the immunogen. A single dose may have merely nanograms of virus particles, or micrograms of bacterial polysaccharides. A vaccine injection, oral drops or nasal spray is mostly water. Other ingredients are added to boost the immune response, to ensure safety or help with storage, and a tiny amount of material is left-over from the manufacturing process. Very rarely, these materials can cause an allergic reaction in people who are very sensitive to them.

<span class="mw-page-title-main">Schott Pharma</span> Company carved out from Schott AG in 2022, stock listed in SDAX

Schott Pharma is a provider of drug containment solutions and delivery systems for injectable drugs. Originally a subsidiary of the glass manufacturer Otto Schott, the company went private and subsequently entered the Frankfurst Stock Exchange in 2023. Headquartered in Mainz, Germany, the company operates in 14 countries.

References

  1. ↑ "ApiJect picks up $111M investment from Royalty Pharma, Jefferies" (website). drugdeliverybusiness.com.
  2. ↑ "ApiJect Systems Corp - Company Profile and News". Bloomberg.com. Retrieved 2021-04-21.
  3. ↑ "ApiJect Systems, Corp., Announces Appointment of Global Branding Leader, Craig Cohon as Chief Strategy Officer". www.prnewswire.com. Retrieved 2021-04-21.
  4. 1 2 "Stamford company may play critical role in COVID vaccine delivery". fox61.com. Retrieved 2021-06-29.
  5. ↑ "Special Feature – PFS & Parenteral Drug Delivery: Self-Injection is Very Much the "New Normal"". Drug Development and Delivery. 2022-05-02. Retrieved 2022-06-27.
  6. ↑ "ASPR celebrates construction of new research and development facility for production of prefilled injectors". Homeland Preparedness News. 2022-04-25. Retrieved 2022-06-27.
  7. ↑ How Soft Plastic Vials Can Help Fight the Coronavirus Outbreak , retrieved 2021-04-22
  8. ↑ ApiJect CEO Expects Therapy to Blunt Coronavirus Death Rate by Summer , retrieved 2021-04-22
  9. ↑ "Trump admin to ramp up syringe production for future COVID-19 vaccine". NBC News. Retrieved 2021-04-21.
  10. 1 2 "U.S. Bets On Small, Untested Company to Deliver COVID Vaccine". Frontline. Retrieved 2021-09-01.
  11. ↑ "4 innovations that found their use case during the pandemic - News". MM+M - Medical Marketing and Media. 2021-03-09. Retrieved 2021-06-29.
  12. ↑ "Trump admin to ramp up syringe production for future COVID-19 vaccine". NBC News. Retrieved 2021-06-29.
  13. 1 2 3 "ApiJect snares $590M government loan for 'Gigafactory' to produce billions of prefilled vaccine injectors per year". FiercePharma. Retrieved 2021-06-29.
  14. ↑ Buckshon, Mark. "$785 million ApiJect Gigafactory in Durham among largest projects in nation to start, despite overall national decline: Dodge" . Retrieved 2021-06-29.
  15. 1 2 "Special Feature – PFS & Parenteral Manufacturing: How COVID-19 Changed the Market". Drug Development and Delivery. 2021-05-03. Retrieved 2021-06-29.
  16. ↑ "The U.S. awarded a firm $1.3 billion to make syringes. Where are they?". NBC News. Retrieved 2021-04-21.
  17. ↑ "The U.S. awarded a firm up to $1.3 billion to make syringes. Where are they?". NBC News. Retrieved 2021-06-29.
  18. ↑ "U.S. Bets On Small, Untested Company to Deliver COVID Vaccine". Frontlin. Retrieved 2021-04-21.
  19. ↑ "Building Resilient Supply Chains, Revitalizing American Manufacturing, and Fostering Broad-Based Growth" (PDF). WhiteHouse.gov. Archived (PDF) from the original on 2021-06-08.
  20. ↑ Whooley, Sean (2021-12-09). "Fareva, ApiJect ink 10-year licensing agreement on fill-finish production lines". Medical Design and Outsourcing. Retrieved 2022-08-05.
  21. ↑ Staff Reports (2022-04-13). "ApiJect Systems opens technology development center in Orlando". Florida Politics . Retrieved 2022-08-05.
  22. ↑ Galford, Chris (2022-04-25). "ASPR celebrates construction of new research and development facility for production of prefilled injectors". Homeland Preparedness News. Retrieved 2022-08-05.
  23. ↑ Keenan, Joseph (2022-05-19). "Syringe maker ApiJect reels in $111M in private investment round". Fierce Pharma. Retrieved 2022-08-05.
  24. ↑ Whooley, Sean (2022-05-18). "ApiJect picks up $111M investment from Royalty Pharma, Jefferies". Drug Delivery Business. Retrieved 2022-08-05.
  25. 1 2 "ApiJect selects IPS for Greenfield blow-fill-seal aseptic manufacturing campus". cleanroomtechnology.com. Retrieved 2021-06-29.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.